Vistagen Therapeutics (VTGN) Non-Current Debt (2016 - 2026)

Vistagen Therapeutics (VTGN) posted Non-Current Debt of $100000.0 for Q1 2026, down 87.25% sequentially from $784200.0 in Q2 2023.

Vistagen Therapeutics (VTGN) Non-Current Debt (2016 - 2026) Analysis & Trends

Vistagen Therapeutics has reported Non-Current Debt for 8 years, with the latest figure at $100000.0 in Q1 2026.

Quarterly Non-Current Debt changed N/A year-over-year to $100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $100000.0 (changed N/A YoY) and the FY2026 annual result came in at $100000.0, changed N/A from the prior year.
Non-Current Debt slipped to $100000.0 in Q1 2026 per VTGN's latest filing, from $784200.0 in the prior quarter.
Over five years, Non-Current Debt peaked at $1.0 million in Q2 2022 and troughed at $100000.0 in Q1 2026.
A 3-year average of $529400.0 and a median of $574550.0 in 2022 frame the typical range for Non-Current Debt.
The widest YoY moves for Non-Current Debt: up 24.44% in 2023, down 24.44% in 2023.
Over 3 years, Non-Current Debt stood at $419100.0 in 2022, then soared by 87.12% to $784200.0 in 2023, then plunged by 87.25% to $100000.0 in 2026.
According to Business Quant data, Non-Current Debt over the past three periods registered $100000.0, $784200.0, and $105300.0 for Q1 2026, Q2 2023, and Q1 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	139.88 Bn	132.03 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.62 Bn	78.62 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	65.28 Bn	60.10 Bn	1.37 Bn	-
4	Moderna	61.39 Bn	56.25 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	42.11 Bn	37.01 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.37 Bn	28.06 Bn	992.69 Mn	-
7	BioNTech SE	28.76 Bn	10.37 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.24 Bn	26.41 Bn	-	8.96 Bn
10	Vistagen Therapeutics	10.39 Mn	10.39 Mn	-	-

Download Data